Positive News SentimentPositive NewsNASDAQ:IMRX Immuneering (IMRX) Stock Price, News & Analysis $3.39 -0.20 (-5.57%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$3.38 -0.02 (-0.44%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Immuneering Stock (NASDAQ:IMRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immuneering alerts:Sign Up Key Stats Today's Range$3.31▼$3.7250-Day Range$1.11▼$3.5952-Week Range$1.00▼$3.87Volume908,546 shsAverage Volume2.56 million shsMarket Capitalization$122.01 millionP/E RatioN/ADividend YieldN/APrice Target$13.25Consensus RatingModerate Buy Company Overview Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Read More Immuneering Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreIMRX MarketRank™: Immuneering scored higher than 82% of companies evaluated by MarketBeat, and ranked 186th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingImmuneering has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageImmuneering has only been the subject of 4 research reports in the past 90 days.Read more about Immuneering's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Immuneering are expected to grow in the coming year, from ($1.86) to ($1.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immuneering is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immuneering is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmuneering has a P/B Ratio of 2.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Immuneering's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.45% of the float of Immuneering has been sold short.Short Interest Ratio / Days to CoverImmuneering has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immuneering has recently decreased by 3.33%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmuneering does not currently pay a dividend.Dividend GrowthImmuneering does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.45% of the float of Immuneering has been sold short.Short Interest Ratio / Days to CoverImmuneering has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immuneering has recently decreased by 3.33%, indicating that investor sentiment is improving. News and Social Media4.2 / 5News Sentiment1.56 News SentimentImmuneering has a news sentiment score of 1.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Immuneering this week, compared to 2 articles on an average week.Search Interest6 people have searched for IMRX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows4 people have added Immuneering to their MarketBeat watchlist in the last 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Immuneering insiders have bought more of their company's stock than they have sold. Specifically, they have bought $311,959.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders22.90% of the stock of Immuneering is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.65% of the stock of Immuneering is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immuneering's insider trading history. Receive IMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter. Email Address IMRX Stock News HeadlinesImmuneering Corporation (NASDAQ:IMRX) CEO Acquires $10,089.30 in StockJuly 4 at 8:48 AM | insidertrades.comImmuneering Corporation (NASDAQ:IMRX) Director Thomas J. Schall Purchases 9,500 SharesJuly 1, 2025 | insidertrades.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.July 6 at 2:00 AM | Brownstone Research (Ad)Immuneering Corporation (NASDAQ:IMRX) Insider Brett Matthew Hall Acquires 6,007 SharesJune 25, 2025 | insidertrades.comImmuneering Corporation (NASDAQ:IMRX) CEO Benjamin J. Zeskind Acquires 21,000 SharesJune 21, 2025 | insidertrades.comAnalysts Set Immuneering Corporation (NASDAQ:IMRX) PT at $13.25June 26, 2025 | americanbankingnews.comWe're A Little Worried About Immuneering's (NASDAQ:IMRX) Cash Burn RateJune 20, 2025 | finance.yahoo.comPre-Market Most Active for Jun 17, 2025 : IMRX, TSLL, VERV, RUN, SQQQ, TQQQ, KO, CRCL, DIS, QBTS, BBAI, NIOJune 19, 2025 | nasdaq.comSee More Headlines IMRX Stock Analysis - Frequently Asked Questions How have IMRX shares performed this year? Immuneering's stock was trading at $2.20 at the beginning of the year. Since then, IMRX stock has increased by 54.1% and is now trading at $3.39. How were Immuneering's earnings last quarter? Immuneering Corporation (NASDAQ:IMRX) posted its earnings results on Monday, May, 5th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.01. When did Immuneering IPO? Immuneering (IMRX) raised $105 million in an IPO on Friday, July 30th 2021. The company issued 7,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities served as the underwriters for the IPO. How do I buy shares of Immuneering? Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immuneering own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immuneering investors own include Tesla (TSLA), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Advanced Micro Devices (AMD), Meta Platforms (META) and Home Depot (HD). Company Calendar Last Earnings5/05/2025Today7/06/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMRX CIK1790340 Webwww.immuneering.com Phone617-500-8080FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$13.25 High Stock Price Target$21.00 Low Stock Price Target$9.00 Potential Upside/Downside+290.9%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$61.04 million Net MarginsN/A Pretax MarginN/A Return on Equity-119.22% Return on Assets-99.22% Debt Debt-to-Equity RatioN/A Current Ratio7.48 Quick Ratio7.48 Sales & Book Value Annual Sales$320 thousand Price / Sales381.27 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book2.55Miscellaneous Outstanding Shares35,990,000Free Float27,745,000Market Cap$122.01 million OptionableNot Optionable Beta0.38 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:IMRX) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.